肽酰基精氨酸脱亚胺酶2基因敲除改善失血性休克生存
该研究利用选择性Pad2基因敲除小鼠,探讨PAD2功能缺失在失血性休克(HS)和心肌梗死(MI)中的作用。HS模型(55%放血)中,Pad2组7天生存率为100%,野生型组为0%(P=0.002)。MI模型中,野生型梗死面积75%大于Pad2组60%(P<0.05),且Pad2组射血分数和缩短分数显著更高(P<0.05)。作者认为PAD2是HS和心脏缺血有前景的未来治疗靶点。
要点
- 致死性失血性休克(55%放血)小鼠中,Pad2敲除组7天生存率100%(5只),野生型组0%(5只),P=0.002。
- 亚致死性失血性休克后24小时,Pad2组心脏β-catenin水平高于野生型组。
- 永久结扎LAD的心肌梗死模型中,野生型梗死面积75%,Pad2组60%(P<0.05)。
- 心肌梗死模型中Pad2组射血分数和缩短分数均显著高于野生型(P<0.05)。
- 作者认为PAD2功能缺失可能通过激活细胞存活通路、提高心脏缺血耐受和改善缺血期心脏功能来改善生存。
适用人群与场景
- 致死性失血性休克小鼠模型:Pad2基因敲除小鼠与野生型小鼠,每组5只,接受55%放血。
- 心肌梗死小鼠模型:Pad2基因敲除小鼠与野生型小鼠,每组9只,永久结扎LAD。
研究设计与关键结果
- 研究类型:动物实验(基因敲除小鼠模型),比较Pad2敲除与野生型在失血性休克和心肌梗死中的效应。
- 失血性休克模型:Pad2组(n=5)7天生存率100%,野生型组(n=5)0%,P=0.002。
- 亚致死性失血性休克后24小时,Pad2组心脏β-catenin水平高于野生型组。
- 心肌梗死模型:野生型组(n=9)梗死面积75%,Pad2组(n=9)60%,P<0.05;Pad2组射血分数和缩短分数显著高于野生型组(P<0.05)。
证据类型、等级与局限
- 证据类型:动物实验(基因敲除小鼠)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为PAD2是未来治疗失血性休克和心脏缺血有前景的靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The peptidylarginine deiminase (PAD) family converts arginine into citrulline through protein citrullination. PAD2 and PAD4 inhibitors can improve survival in hemorrhagic shock (HS). However, the impact of isoform-specific PAD inhibition in improving survival has not been studied. In this study, we utilize selective Pad2 knockout mice to elucidate loss of function of PAD2 leads to pro-survival effect in HS.
METHODS: HS: Pad2 and wild-type (WT) mice (n = 5/group) were subjected to lethal HS (55% volume hemorrhage). Survival was monitored over 7 days. Myocardial infarction (MI): Pad2 and WT mice (n = 9/group) were subjected to MI by permanent LAD ligation to examine the effect of ischemia on the heart. After 24 h cardiac function and infarct size were measured.
RESULTS: HS: Pad2 mice demonstrated 100% survival compared with 0% for WT mice (P = 0.002). In a sub-lethal HS model, cardiac β-catenin levels were higher in Pad2 compared with WT after 24 h. MI: WT mice demonstrated larger MI (75%) compared with Pad2 (60%) (P < 0.05). Pad2 had significantly higher ejection fraction and fractional shortening compared with WT (P < 0.05).
CONCLUSIONS: Pad2 improves survival in lethal HS. Possible mechanisms by which loss of PAD2 function improves survival include the activation of cell survival pathways, improved tolerance of cardiac ischemia, and improved cardiac function during ischemia. PAD2 is promising as a future therapeutic target for the treatment of HS and cardiac ischemia.
参考来源
- Zhou J, Biesterveld BE, Li Y, et al. Peptidylarginine Deiminase 2 Knockout Improves Survival in hemorrhagic shock. Shock. 2020. PMID: 31764615. doi:10.1097/SHK.0000000000001489
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。